Kamada Presents Data On Inhaled Alpha-1 Antitrypsin In Cystic Fibrosis Patients At The European Respiratory Society Meeting 2009, Vienna

Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that data on its next-generation alpha-1 antitrypsin (Inhaled-AAT) in cystic fibrosis patients was presented, at the Annual Congress of the European Respiratory Society (ERS) 2009, Vienna.